abstract |
The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure. |